window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 21, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Phase 3

  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Elicio misses Phase 2 endpoint but advances Phase 3 plan for pancreatic cancer immunotherapy

    Elicio Therapeutics has reported that its Phase 2 Amplify-7P trial [...]

    June 15, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Opinion & Events,Therapeutic Areas

    Abivax to present nine obefazimod studies at DDW as Phase 3 ulcerative colitis data build

    Abivax will present nine scientific abstracts on obefazimod at Digestive [...]

    May 5, 2026
  • Clinical & Regulatory,Therapeutic Areas

    Chiesi gains CHMP backing for lomitapide in children with rare cholesterol disorder

    Chiesi Global Rare Diseases has received a positive CHMP opinion [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Hansa Biopharma reports 135% Q4 revenue growth and BLA submission for imlifidase

    Hansa Biopharma has reported a 135% increase in fourth-quarter revenue [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Hans Schambye appointed as CEO of BOOST Pharma as BT‑101 advances toward Phase 3

    BOOST Pharma has appointed Hans Schambye as its new chief [...]

    May 5, 2026
  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory

    Single-cell analysis highlights molecular subgroups in endometriosis that could inform clinical trials

    Endometriosis is typically treated as a single condition, yet patients [...]

    May 5, 2026
  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory

    Newron expands evenamide IP protection with new EU composition of matter patent

    Newron has expanded the intellectual property protection for its lead [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Manufacturing & Supply Chain,Therapeutic Areas

    Symbiosis manufactures first commercial-scale batch at new Stirling facility

    Symbiosis Pharmaceutical Services has completed its first commercial-scale manufacturing run [...]

    May 5, 2026
  • Clinical & Regulatory,Therapeutic Areas

    UCB reports positive phase 3 Gemz results as fenfluramine cuts seizure frequency in CDKL5 deficiency disorder

    UCB has reported positive findings from the Gemz phase 3 [...]

    May 5, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    GSK’s depemokimab backed by Phase 3 data ahead of FDA decision in asthma and sinusitis

    Phase 3 data for GSK’s depemokimab appear to support the [...]

    May 5, 2026
Previous234Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Eleva separates biologics platform from Factor H therapy
    Categories: Advanced Therapies, Biotech & Pharma Business, Pharmaceuticals and therapeutics, Research & Development
  • ENA Respiratory begins Phase 2a dosing of nasal antiviral INNA-051
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Circio raises NOK 200M (€18.6M) to advance in vivo CAR-T programme
    Categories: Advanced Therapies, Biotech & Pharma Business, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top